Abstract: Addition of a dicarboxylic acid such as adipic acid to a cyanamide aqueous solution brings about improvement in storage stability of the cyanamide aqueous solution.

Abstract: The invention provides benzo[b]thiophene compounds, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, and cardiovascular-related pathological conditions including hyperlipidemia and related cardiovascular pathologies.

Abstract: The present invention relates to an aqueous cleaning composition containing(a) 1 to 10 weight % of at least one surfactant selected from the group consisting of anionic surfactants and ethoxylated nonionic surfactants and mixtures thereof;(b) 0.2 to 10 weight % of a biostatic agent such as a C.sub.2 -C.sub.20 alkyl trimethyl ammonium halide, a C.sub.8 -C.sub.16 alkyl dimethyl benzyl ammonium halide, a polyhexamethylene biguanide hydrochloride, a 3-(trialkoxysilyl)propyl C.sub.14 -C.sub.20 alkyl dimethyl ammonium halide, ketoconazole, and zinc-bis(2-pyridinethiol 1-oxide); and(c) the balance being water; wherein said liquid cleaning composition does not contain a pigment, a chlorine containing bleach, peroxygen bleach, hydrogen peroxide, builder, water soluble or water dispersible organic binding agent, sequestering agent, acid dye, C.sub.8 -C.sub.18 fatty acid monoester of diglycerol, C.sub.8 -C.sub.

Abstract: Novel secoaporphine compounds having the formula I ##STR1## wherein a) R.sub.1, R.sub.2 and R.sub.3, R.sub.4 are each methyl group; or b) R.sub.1, R.sub.2, and R.sub.4 are each methyl group; R.sub.3 is benzyl, ethyl or allyl; or c) R.sub.1, R.sub.2, and R.sub.3 are each hydrogen, R.sub.4 is methyl; or d) R.sub.1 and R.sub.2 are each hydrogen, R.sub.3 is benzyl, R.sub.4 is methyl; or e) R.sub.1 and R.sub.2 are each hydrogen, R.sub.3 is cyano, R.sub.4 is methyl group, and a salt thereof with a pharmaceutically acceptable acid. The novel compounds are useful in the treatment of arrhythmia.

Abstract: A butenoic acid compound of the following formula: ##STR1## in which Z is O, S, vinylene or azomethyne, A is an alkylene group and J is phenyl group, is a useful in treating heart disease.

Abstract: A butenoic or propenoic acid derivative having the following formula in which G is an aryl or a heterocyclic ring, R11 and R12 are hydroben or an alkyl, X is sulfur or oxygen, R2 and R3 are hydrogen, an substituent such as an alkyl and J is pyridyl or phenyl having substituents and a heterocyclic ring may be formed between R2, R3 and J is provided here and is useful in the pharmacological field.

Abstract: A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.

Abstract: Ulcerative conditions of the gastro-intestinal tract, e.g., antiinflammatory-drug-induced ulcers, are treated or prevented by the administration of a potassium channel activator. Methods and combination products are also disclosed for the treatment of inflammatory conditions without causing ulceration of the gastrointestinal tract.

Abstract: Compounds of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are independently fluorine, chlorine or bromine atom, and R.sup.3 is a C.sub.4 -C.sub.7 alkyl having at least a branch at the C.sub.1 position, exhibit K.sup.+ channel opening activity and are useful as hypotensive agents and coronary vasodilators.

Abstract: Compounds of the general formula: ##STR1## and physiologically acceptable salts, and hydrates, N-oxides and bioprecursors of such compounds and such salts in whichR.sub.1 and R.sub.2, which may be the same or different, represent hydrogen or lower alkyl, cycloalkyl, aralkyl or lower alkenyl groups, or lower alkyl groups interrupted by an oxygen atom or a group ##STR2## in which R.sub.4 represents hydrogen or lower alkyl; or R.sub.1 and R.sub.2 may, together with the nitrogen atom to which they are attached form a heterocyclic ring which may contain the hetero functions --O-- and ##STR3## R.sub.3 represents hydrogen, lower alkyl, alkenyl or alkoxyalkyl; X represents --O--, --S-- or --CH.sub.2 -- or ##STR4## where R.sub.5 is hydrogen or lower alkyl; Y represents .dbd.S, .dbd.O, .dbd.NR.sub.6 or .dbd.CHR.sub.7 ;in which R.sub.6 represents hydrogen, nitro, cyano, lower alkyl, aryl, arylsulphonyl or lower alkylsulphonyl; R.sub.

Abstract: Novel compounds of the formula ##STR1## and tautomers thereof, wherein at least one of R.sub.2, R.sub.3 and R.sub.4 is a strong electron withdrawing group, are disclosed. These compounds possess potassium channel activating activity and, as such, are useful as antihypertensive agents. Advantageously, the compounds of the present invention have shown less cardiac effects than known potassium channel activators.Also disclosed is a process for preparing these and other compounds.

Abstract: Novel compounds of the formula ##STR1## and tautomers thereof are disclosed. These compounds possess potassium channel blocking activity and, as such, are useful as antiarrhythmic agents.

Abstract: The invention relates to a plant-protective solution containing 2.5 to 40 % by weight of one or more water-insoluble plant-protective ingredient(s) 20 to 71.5 % by weight of dimethylformamide and/or dimethylsulfoxide and/or acetone as water-miscible solvent, 10 to 71.5 % by weight of furfurol and/or furfuryl alcohol as partially water-miscible solvent, 1 to 15 % by weight of commonly used additives such as anionic and/or nonionic surface active agents and macromolecules.The invention also relates to the ready-for-use plant-protective suspension containing 0.2 to 10 % by weight of one or more water-insoluble plant-protective ingredient(s) with a particle size of 0.1 to 50 .mu.m, 0 to 60 % by weight of a fertilizer, 0.2 to 10 % by weight of dimethylformamide and/or dimethylsulfoxide and/or acetone as water-miscible solvent, 0.2 to 10 % by weight of furfurol and/or furfuryl alcohol as partially water-miscible solvent, 0.05 to 2.

Abstract: Compounds having the formula: ##STR1## are antagonists of leukotrienes of C.sub.4, D.sub.4, E.sub.4 and the slow reacting substance of anaphylaxis.As such, these compounds will be useful as anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

Abstract: Acylated cyanamide compounds useful for ethanol deterrence of the formula RCONHCN, wherein R is a lipophilic acyl group or is derived from an (N-substituted)-alpha-aminoacyl group.

Abstract: The present invention provides novel insecticidal dibenzoyl-tert-butylcarbazonitrile compounds and a method for the preparation thereof. It also provides methods for controlling insects with said dibenzoyl-tert-butylcarbazonitrile compounds and for protecting growing plants, crops, trees, shrubs and ornamentals, from attack by said insects.

Abstract: 1-Aryloxy-3-(substituted aminoalkylamino)-2-propanols and pharmaceutically acceptable salts thereof have .beta.-adrenergic blocking activity with some cardioselectivity and hence are useful as anti-hypertensive, antianginal, antiarrhythmic and cardioprotective agents and in the treatment of elevated intraocular pressure such as glaucoma.

Abstract: The invention relates to novel amides of [(5,6-dichloro-3-oxo-9a-substituted-2,3,9,9a-tetrahydrofluoren-7-yl)oxy]ac etic acids, their derivatives, and their salts. The compounds are useful for the treatment and prevention of injury to the brain and of edema due to head trauma, stroke (particularly ischemic), arrested breathing, cardiac arrest, Reye's syndrome, cerebral thrombosis, cerebral embolism, the neurological problems caused by AIDS, cerebral hemorrhage, cerebral tumors, encephalomyelitis, spinal cord injury, hydroephalus, post-operative brain injury trauma, edema due to cerebral infections, various brain concussions and elevated intracranial pressure.

Abstract: Acylated cyanamide compounds useful for ethanol deterrence of the formula RCONHCN, wherein R is a lipophilic acyl group or is derived from an (N-substituted)-alpha-aminoacyl group.

Abstract: This invention relates to novel cyanoguanidine compounds and the intermediate N'-cyano-N-(1,2,3,4-tetrahydro-1-naphthyl)-S-methylisothiourea. These novel compounds are useful as animal growth promoting agents.

Abstract: This invention relates to novel cyanoguanidine compounds and the intermediate N'-cyano-N-(1,2,3,4-tetrahydro-1-naphthyl)-S-methylisothiourea. These novel compounds are useful as animal growth promoting agents.

Abstract: This invention relates to a novel cyanoguanidine compound, N'-cyano-N-(1,2,3,4-tetrahydro-1-naphthyl)guanidine, which is useful as an animal growth promoting agent.

Abstract: Alkanol derivatives corresponding to the general formula IR.sup.1 R.sup.2 N--(CH.sub.2).sub.m --Q--CH.sub.2 X--CH.sub.2 --Y--(CH.sub.2).sub.n --NHR.sup.3 (I)which have a highly selective action on histamine-H.sub.2 receptors are described. Due to this action, these compounds may advantageously be used for treatment of diseases caused by raised gastric secretion.

Abstract: Cystamine derivatives of the formula: ##STR1## [wherein n represents 2 or 3, R.sup.1 and R.sup.2 each represents a hydrogen atom, or an alkyl group optionally substituted by a hydroxy, amino, alkylamino or dialkylamino group, or represents a cycloalkyl or aryl group, and X.sup.1 represents a group selected from the formulae .dbd.N--CN, .dbd.N--NO.sub.2, .dbd.N--COR.sup.3, .dbd.N--COOR.sup.3, .dbd.N--NH--CONH.sub.2, .dbd.N--SO.sub.2 R.sup.3, .dbd.CH--NO.sub.2, .dbd.CH--SO.sub.2 R.sup.3, .dbd.C(CN).sub.2, .dbd.C(CN)COOR.sup.3 and .dbd.C(CN)CONH.sub.2 (wherein R.sup.3 represents an alkyl or aryl group), or R.sup.1 represents a hydrogen atom, R.sup.2 represents an alkyl group optionally substituted by a hydroxy, amino, alkylamino or dialkylamino group, or represents a cycloalkyl or aryl group and X.sup.1 represents an oxygen or sulphur atom] have been found to be useful in the promotion of the growth of non-human animals including birds.

Abstract: A class of naphthalene aminoalkylene ether and thioether compounds exhibiting pharmacological activity including anti-secretory and anti-ulcerogenic activity, pharmaceutical compositions comprising these compounds, and methods for the treatment of gastrointestinal hyperacidity and ulcerogenic disorders in mammals using said compositions are disclosed.

Abstract: 1-Cyano-3-(fluoroalkyl)guanidines of the formula: ##STR1## in which R.sub.1, R.sub.2 and R.sub.3 are the same or different members of the class of hydrogen, fluorine, lower alkyl or lower alkenyl provided that at least one member is fluorine or fluoro-substituted alkyl or alkenyl. These compounds are useful for their biological properties, e.g. in treating elevated blood pressure and Parkinson's disease.